Pulmonary vasodilators.
Pulmonary vasodilators are an important treatment for pulmonary arterial hypertension. They reduce pulmonary artery pressure; improve hemodynamic function; alter ventilation/perfusion matching in the lungs; and improve functional quality of life, exercise tolerance, and survival in patients with severe pulmonary arterial hypertension. This paper reviews the currently available pulmonary vasodilators and those under development, many of which can be administered via inhalation. I will also give an overview of the clinical pharmacology of, the indications for, and the evidence supporting pulmonary vasodilators, their delivery via inhalation, and potential toxic and adverse effects.
Siobal
Mark S
MS
Respiratory Care Services, San Francisco General Hospital, 1001 Potrero Avenue, NH GA2, San Francisco, CA 94110, USA. msiobal@sfghsom.ucsf.edu
D019317:Evidence-Based Medicine; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D011651:Pulmonary Artery / Q000503:physiopathology*; D016896:Treatment Outcome; D014481:United States; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use
D014665:Vasodilator Agents